# INTERNATIONAL FILING STRATEGY - CLERKY PATENT
## Global Patent Protection Roadmap

**Core Application**: UK Patent Application - Clerky AI Clinical Decision Support  
**Priority Date**: October 17, 2023  
**Applicant**: CLERKYAI LTD  
**Strategy Date**: January 2025

---

## üåç EXECUTIVE SUMMARY

This document outlines a strategic international patent filing plan for Clerky's AI-powered clinical decision support platform. The strategy balances global market protection with cost optimization, prioritizing key markets based on commercial potential, regulatory environment, and competitive landscape.

---

## üìÖ FILING TIMELINE

### Critical Deadlines

#### Priority Year (October 17, 2023 - October 17, 2024)
- ‚úÖ **UK Application Filed**: October 2024 (within priority window)
- **PCT Application Window**: Must file by October 17, 2024 to claim priority

#### Post-Priority Deadlines
- **PCT National Phase**: 30/31 months from priority date (April 2026)
- **European Regional Phase**: 31 months from priority date (May 2026)
- **Direct National Filings**: Various deadlines if PCT not filed

### Recommended Timeline

#### Immediate Actions (Q1 2025)
- **UK Prosecution**: Respond to search report and examination
- **PCT Preparation**: Prepare PCT application for international filing
- **Market Research**: Finalize target country analysis

#### Short Term (Q2-Q3 2025)
- **PCT Filing**: File within 12 months of UK priority if desired
- **European Patent Application**: Direct EPO filing or via PCT
- **US Provisional**: Consider US provisional application

#### Medium Term (2026-2027)
- **PCT National Phase**: Enter key markets via PCT route
- **Direct National Filings**: Countries not covered by PCT
- **Prosecution Management**: Coordinate global prosecution strategy

---

## üéØ TARGET MARKETS ANALYSIS

### Tier 1 Markets (Essential)

#### United States
- **Market Potential**: Largest healthcare software market globally
- **Regulatory Environment**: FDA medical device software pathway established
- **Patent System**: Strong IP protection, high litigation environment
- **Filing Strategy**: PCT ‚Üí US National Phase
- **Estimated Costs**: $15,000-25,000 (application + prosecution)
- **Priority Justification**: 40% of global healthcare software revenue

#### European Union (via EPO)
- **Market Potential**: Large, harmonized market with strong healthcare systems
- **Regulatory Environment**: CE marking for medical devices, GDPR compliance
- **Patent System**: Unified Patent Court provides strong enforcement
- **Filing Strategy**: PCT ‚Üí European Regional Phase
- **Estimated Costs**: ‚Ç¨20,000-35,000 (application + prosecution + validation)
- **Priority Justification**: 30% of global healthcare software market

### Tier 2 Markets (Important)

#### Canada
- **Market Potential**: Advanced healthcare system, early AI adopter
- **Regulatory Environment**: Health Canada medical device pathway
- **Patent System**: Similar to US system, lower litigation risk
- **Filing Strategy**: PCT ‚Üí Canadian National Phase
- **Estimated Costs**: CAD $10,000-20,000
- **Priority Justification**: English-speaking market, proximity to US

#### Australia
- **Market Potential**: Advanced healthcare technology adoption
- **Regulatory Environment**: TGA medical device regulations
- **Patent System**: Innovation patent system available
- **Filing Strategy**: PCT ‚Üí Australian National Phase
- **Estimated Costs**: AUD $15,000-25,000
- **Priority Justification**: English-speaking market, AI-friendly regulation

#### Japan
- **Market Potential**: Large healthcare market, technology-focused
- **Regulatory Environment**: PMDA medical device approval process
- **Patent System**: Strong IP protection, technical examination
- **Filing Strategy**: PCT ‚Üí Japanese National Phase
- **Estimated Costs**: ¬•2,000,000-4,000,000 ($15,000-30,000)
- **Priority Justification**: Innovation in healthcare technology

### Tier 3 Markets (Opportunistic)

#### Singapore
- **Market Potential**: Regional hub for Southeast Asia
- **Regulatory Environment**: HSA medical device pathway
- **Patent System**: Fast-track examination available
- **Filing Strategy**: Direct national filing or PCT
- **Estimated Costs**: SGD $8,000-15,000
- **Priority Justification**: Gateway to Asian markets

#### Germany (Direct National)
- **Market Potential**: Largest European healthcare market
- **Regulatory Environment**: BfArM medical device regulations
- **Patent System**: Strong technical examination
- **Filing Strategy**: Direct national filing (alternative to EPO)
- **Estimated Costs**: ‚Ç¨10,000-20,000
- **Priority Justification**: Key European market with strong IP protection

---

## üìã FILING STRATEGY OPTIONS

### Option 1: PCT Route (Recommended)

#### Advantages
- **Cost Efficiency**: Single application covers multiple countries
- **Flexibility**: 30-month window to decide on national phase entries
- **Search Benefits**: International search report provides patent landscape insight
- **Quality**: International preliminary examination improves patent quality

#### Process
1. **PCT Application**: File within 12 months of UK priority
2. **International Search**: Conducted by International Searching Authority (ISA)
3. **Publication**: Application published 18 months from priority
4. **National Phase**: Enter selected countries by 30/31 months

#### Estimated Costs
- **PCT Filing**: $3,000-5,000
- **National Phase** (per country): $10,000-30,000
- **Total for Tier 1+2**: $80,000-150,000

### Option 2: Direct National Filings

#### Advantages
- **Speed**: Faster prosecution in some countries
- **Cost Control**: Pay only for selected countries upfront
- **Local Expertise**: Direct relationship with local patent attorneys

#### Disadvantages
- **Complexity**: Multiple applications to manage
- **Higher Costs**: Individual filings more expensive
- **Time Pressure**: Must file within 12 months of priority

#### Estimated Costs
- **Per Country**: $10,000-30,000
- **Total for Tier 1+2**: $100,000-200,000

### Option 3: Hybrid Approach

#### Strategy
- **PCT for Major Markets**: US, EU, Canada, Australia, Japan
- **Direct Filings**: UK (already filed), select national markets
- **Regional Applications**: EPO for European coverage

#### Benefits
- **Optimized Costs**: Best route for each market
- **Strategic Flexibility**: Tailored approach by jurisdiction
- **Risk Management**: Diversified filing strategy

---

## üí∞ COST ANALYSIS

### 5-Year Budget Forecast

#### Year 1 (2025): Foundation
- **UK Prosecution**: ¬£3,000-5,000
- **PCT Filing**: $4,000-6,000
- **Professional Fees**: $5,000-8,000
- **Total**: ¬£10,000-15,000 ($12,000-18,000)

#### Year 2 (2026): National Phase Entry
- **US National Phase**: $20,000-30,000
- **European Regional Phase**: ‚Ç¨25,000-40,000
- **Canada/Australia**: $15,000-25,000 each
- **Total**: $75,000-125,000

#### Year 3-5 (2027-2029): Prosecution & Maintenance
- **Global Prosecution**: $30,000-50,000 annually
- **Patent Grants**: $20,000-40,000 total
- **Maintenance Fees**: $5,000-10,000 annually
- **Total**: $40,000-70,000 annually

#### Total Investment (5 Years)
- **Conservative**: $200,000-250,000
- **Comprehensive**: $300,000-400,000

### Return on Investment (ROI)

#### Patent Value Scenarios
- **Licensing Revenue**: 10-20% of product revenue
- **Market Protection**: Premium pricing and competitive barriers
- **Strategic Value**: Partnership leverage and exit multiples

#### Break-Even Analysis
- **Required Revenue**: $1M-2M annually to justify full international strategy
- **Market Size**: Achievable with 1-5% market share in target segments
- **Timeline**: 3-5 years to reach break-even on patent investment

---

## üîç PROSECUTION STRATEGY

### Claim Strategy by Jurisdiction

#### United States
- **Focus**: Technical implementation details and algorithms
- **Considerations**: 35 USC 101 (patent eligible subject matter)
- **Strategy**: Emphasize technical improvements and computer-specific solutions

#### European Union
- **Focus**: Technical character and non-obvious combinations
- **Considerations**: EPC Article 52 (excluded subject matter)
- **Strategy**: Highlight technical problems solved and unexpected results

#### Other Jurisdictions
- **Adaptation**: Tailor claims to local patent law requirements
- **Coordination**: Maintain consistency while optimizing for each jurisdiction
- **Local Counsel**: Engage experienced local patent attorneys

### Portfolio Management

#### Centralized Coordination
- **Lead Counsel**: UK patent attorney as coordinating counsel
- **Local Counsel**: Experienced attorneys in each jurisdiction
- **Communication**: Regular coordination calls and status updates
- **Documentation**: Centralized file management and decision tracking

#### Quality Control
- **Claim Consistency**: Ensure core claims are protected globally
- **Prior Art**: Coordinate prior art disclosure across jurisdictions
- **Prosecution History**: Avoid inconsistent arguments between jurisdictions

---

## üåê REGIONAL CONSIDERATIONS

### United States
- **Patent Trial and Appeal Board (PTAB)**: Consider patent eligibility challenges
- **Continuation Practice**: Plan for continuation applications
- **Litigation Environment**: Strong enforcement but high costs

### European Union
- **Unified Patent Court (UPC)**: Consider opt-out strategy for initial period
- **Validation Strategy**: Select key EU countries for cost optimization
- **Brexit Impact**: UK no longer covered by EPO grants

### Asia-Pacific
- **China**: Consider separate filing if market entry planned
- **ASEAN**: Singapore as regional hub for filing strategy
- **Translation Costs**: Factor in language requirements

---

## üìä RISK ASSESSMENT

### Patent Risks

#### Invalidity Challenges
- **Prior Art**: Comprehensive search before each filing
- **Obviousness**: Emphasize non-obvious combinations
- **Mitigation**: Strong prosecution strategy and claim differentiation

#### Design-Around Risk
- **Broad Claims**: Ensure key innovations are broadly protected
- **Continuation Strategy**: Plan additional filings for improvements
- **Trade Secrets**: Protect implementation details not disclosed in patents

### Commercial Risks

#### Market Entry Delays
- **Regulatory**: Medical device approval timelines may delay market entry
- **Competitive**: Fast-moving market requires timely patent protection
- **Mitigation**: File early and maintain broad protection

#### Cost Overruns
- **Prosecution Complexity**: Some jurisdictions may require extensive prosecution
- **Currency Fluctuation**: International filing costs subject to exchange rates
- **Budget Planning**: Conservative estimates with contingency reserves

---

## ‚úÖ RECOMMENDATIONS

### Immediate Actions (Q1 2025)
1. **PCT Preparation**: Prepare PCT application based on UK priority
2. **Attorney Selection**: Identify lead international patent attorney
3. **Budget Approval**: Secure funding for international filing strategy

### Short-Term Strategy (2025-2026)
1. **PCT Filing**: File PCT application by October 2025 (recommended)
2. **Market Validation**: Confirm target markets based on commercial progress
3. **National Phase Planning**: Prepare for national phase entries in 2026

### Long-Term Strategy (2027-2030)
1. **Portfolio Expansion**: File continuation and improvement applications
2. **Enforcement Planning**: Develop enforcement strategy for key markets
3. **Licensing Program**: Establish international licensing program

---

## üéØ SUCCESS METRICS

### Filing Metrics
- **Coverage**: Patent applications in 5-7 key markets
- **Grant Rate**: 80%+ grant rate across jurisdictions
- **Timeline**: All key markets covered within 3 years of priority

### Commercial Metrics
- **Market Entry**: Active in 3+ countries within 5 years
- **Revenue Protection**: Patents cover 80%+ of revenue-generating markets
- **Licensing Revenue**: 10%+ of total revenue from patent licensing

---

**Strategy Status**: Ready for Implementation  
**Next Review**: Quarterly updates based on commercial progress  
**Key Decision Point**: PCT filing by October 2025  
**Date**: January 2025 